(Q44517938)

3 December 2017

title

Oral supplementation corrects plasma lysine concentrations in lysinuric protein intolerance (English)

1 reference

3 December 2017

Mari Lukkarinen

1

1 reference

3 December 2017

Kirsti Näntö-Salonen

2

1 reference

3 December 2017

Kari Pulkki

3

1 reference

3 December 2017

Maija Aalto

4

1 reference

3 December 2017

Olli Simell

5

1 reference

3 December 2017

publication date

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

52

1 reference

3 December 2017

issue

7

1 reference

3 December 2017

page(s)

935-938

1 reference

Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Ferritinemia with subnormal iron stores in lysinuric protein intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Lysinuric protein intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Lysinuric protein intolerance mutation is expressed in the plasma membrane of cultured skin fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Lysinuric protein intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Varicella and varicella immunity in patients with lysinuric protein intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Hyperdibasicaminoaciduria, hyperammonemia, and growth retardation: Treatment with arginine, lysine, and citrulline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Skeletal manifestations of lysinuric protein intolerance. A follow-up study of 29 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Osteoporosis in lysinuric protein intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

The metabolic roles, pharmacology, and toxicology of lysine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Inhibitory effect of intravenous lysine infusion on urea cycle metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

A scheme for the interpretation of primary and secondary disturbances of plasma and urinary amino acid profiles. A possible way to an expert system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Lysinuric protein intolerance. Urinary amino acid excretion at 2 and 9 days of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Influence of lysine on urea cycle activity and orotate formation in the isolated perfused rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

Effect of lysine infusion on urea cycle in lysinuric protein intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900089-1

10.1016/S0026-0495(03)00089-1

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference